Clinical Trial Update: Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating once-daily BAY 59-7939 for prevention of venous thromboembolism after elective total hip replacement; the trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• BAY 59-7939 (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED